secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001104659-23-002091
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron: FY2022 EYLEA US sales $6.26B (+8%), Q4 $1.50B (-3%); expects $30M IPR&D charge
--------------------------------------------------------------------------------

- FY2022 EYLEA US net product sales ~$6.26B (+8% YoY); Q4 2022 ~$1.50B (-3% YoY).
- Q4 EYLEA negatively impacted by short-term shift to off-label compounded Avastin and temporary closure of co-pay assistance fund; reversal beginning per Dec 2022 market data.
- Expects ~$30M IPR&D charge from CytomX collaboration, reducing Q4 2022 GAAP/non-GAAP diluted EPS by ~$0.21.
- Aflibercept 8 mg BLA submitted for wAMD and DME using priority review voucher; potential FDA approval by late August 2023.
- Dupixent approved in 2022 for AD infants (6mo-5yr), EoE, prurigo nodularis; sBLA submitted for CSU in biologic-naïve patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000110465923002091/0001104659-23-002091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000110465923002091/tm231703d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-002091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer